Introduction: Critical Indigenous Theory

Aileen Moreton-Robinson introduces the essays in the Critical Indigenous Theory section of the journal

Anadolu destanı

Taha Toros Arşivi, Dosya No: 185, 186) Eyuboğlu, Orhan-Cemal-Osman Zeki-Bedri Rahmi-Mualla-SabahattinUnutma İstanbul projesi İstanbul Kalkınma Ajansı'nın 2016 yılı "Yenilikçi ve Yaratıcı İstanbul Mali Destek Programı" kapsamında desteklenmiştir. Proje No: TR10/16/YNY/010

L\u2019esperienza dell\u2019immagine: il Denkraum der Besonnenheit di Aby Warburg

Il lavoro si fonda sull\u2019idea che il periodo del ricovero (1921-1924) di Aby Warburg nella clinica di Bellevue (Kreuzlingen), allora diretta da Ludwig Binswanger, debba essere considerato centrale per lo sviluppo teorico dello studioso amburghese. Piuttosto che liquidare come lungo momento di buio gli anni della malattia, si \ue8 ritenuto utile riflettere sulle connessioni tra l\u2019esperienza e l\u2019attitudine esistenziale di Warburg e gli sviluppi della sua ricerca. Prendendo in esame la celebre conferenza sul rituale del serpente (A lecture on Serpent Ritual) che lo storico dell\u2019arte tedesco tenne nel 1923 a Kreuzlingen, con il consenso di Binswanger, per attestare la sua guarigione davanti a un pubblico di medici e pazienti, ci si imbatte infatti in un concetto che diviene centrale per attraversare la produzione frammentaria e asistematica warburghiana. Se infatti il tema del Denkraum der Besonnenheit, compare per la prima volta nel 1920 (Divinazione antica pagana in testi ed immagini dell\u2019et\ue0 di Lutero), soltanto nella conferenza sul serpente prender\ue0 le sembianze di un processo dialettico - al contempo metodologico, scientifico e terapeutico - che tiene insieme e rielabora costantemente le polarit\ue0 costitutive dell\u2019essere umano. Il primo capitolo presenta l\u2019autore all\u2019interno della sua cornice storico-teorica, mettendo in evidenza le nefaste ricadute che ebbe lo scoppio della Prima Guerra Mondiale sulle certezze scientifiche e metodologiche di Warburg, sul suo rapporto privilegiato con l\u2019Italia e l\u2019arte rinascimentale e sulla sua passione per la migrazione storica, geografica e simbolica del sapere. In quello che si lascia definire come percorso di autoguarigione, Ludwig Binswanger ebbe senza dubbio un ruolo determinante, introducendo il suo paziente, da sempre ossessionato dalla distanza conoscitiva tra soggetto e oggetto, al metodo fenomenologico in occasione della conferenza del 1922 (Sulla fenomenologia; cber Ph\ue4nomenologie) alla quale Warburg fu invitato ad assistere. Il secondo capitolo \ue8 una disamina accurata delle ricorrenze del Denkraum der Besonnenheit negli scritti dello studioso amburghese per seguire le mutazioni sostanziali che la locuzione sub\uec dopo la permanenza a Kreuzlingen. Analizzando l\u2019etimologia greca di Besonnenheit, sophrosyne, si coglie l\u2019essenza della proposta warburghiana che, in linea con la prospettiva herderiana, riprende il significato della parola greca al momento della sua nascita, quando mostra un legame intrinseco tra corpo e intelletto che subito perder\ue0 fino a simboleggiare l\u2019esatto opposto, la volont\ue0 umana di dominare le passioni con la forza della ragione. Il terzo capitolo \ue8 dedicato alla dimensione temporale della dialettica del Denkraum all\u2019interno dell\u2019ultima, incompiuta opera di Warburg, l\u2019atlante Mnemosyne, che nasce proprio dall\u2019esigenza di tematizzare un paradigma evolutivo delle forme simboliche (storiche/artistiche/antropologiche) alternativo a una concezione di progresso lineare e unidirezionale. Lo sviluppo spazio-temporale delle forme simboliche \ue8 caratterizzato da uno sviluppo discontinuo soggetto alla regressione, la dimensione in cui l\u2019acquisizione di nuove funzioni vitali pu\uf2 avvenire soltanto tramite la scomparsa di elementi preesistenti. I pannelli introduttivi A (orientamento), B (microcosmo/macrocosmo) e C (progresso tecnico) risultano emblematici sia nel convogliare la costellazione concettuale presa in esame nel corso della trattazione, sia nell\u2019illustrare il funzionamento del modello di \u201cevoluzione regressiva\u201d, una dialettica tesa tra il guadagno e la perdita che non ha esclusivamente matrici umanistiche ma si inserisce nel vivo confronto tra biologia e scienze dello spirito, grazie al quale Warburg si confronter\ue0 proficuamente con le teorie di Darwin ed Haeckel

The Local, the ‘Indigenous’ and the Limits of Rethinking Peacebuilding

© 2021 Informa UK Limited, trading as Taylor & Francis Group. This is the accepted manuscript version of an article which has been published in final form at https://doi.org/10.1080/17502977.2021.1882755Recent critical perspectives on peacebuilding have sought to shed light on experiences so far marginalized by mainstream approaches. In particular, critics have pushed peacebuilding towards radically different ways of thinking about governance, conflict and peace, by engaging with narratives, experiences and knowledge coming from societies perceived as not invested in modernity or liberalism, such as Indigenous communities. Whilst this may force theory to confront questions of human-centrism, colonial erasure, and structural violence, turning to Indigeneity without questioning the impact of liberal peace ‘thinking', might further elicit marginalization and appropriation, and simply ‘save’ liberal peacebuilding through the back door.Peer reviewe

Smoke, curtains and mirrors: the production of race through time and title registration

This article analyses the temporal effects of title registration and their relationship to race. It traces the move away from the retrospection of pre-registry common law conveyancing and toward the dynamic, future-oriented Torrens title registration system. The Torrens system, developed in early colonial Australia, enabled the production of ‘clean’, fresh titles that were independent of their predecessors. Through a process praised by legal commentators for ‘curing’ titles of their pasts, this system produces indefeasible titles behind its distinctive ‘curtain’ and ‘mirror’, which function similarly to magicians’ smoke and mirrors by blocking particular realities from view. In the case of title registries, those realities are particular histories of and relationships with land, which will not be protected by property law and are thus made precarious. Building on interdisciplinary work which theorises time as a social tool, I argue that Torrens title registration produces a temporal order which enables land market coordination by rendering some relationships with land temporary and making others indefeasible. This ordering of relationships with land in turn has consequences for the human subjects who have those relationships, cutting futures short for some and guaranteeing permanence to others. Engaging with Renisa Mawani and other critical race theorists, I argue that the categories produced by Torrens title registration systems materialise as race

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation